Clinical Research Directory

Inclusion Criteria: 1. Participant, or the participant's legal representative, who voluntarily understands and signs an informed consent form prior to any study specific assessment or procedure. 2. Aged 12 years or older at the time of signing the informed consent form (ICF), with no upper age limit. 3. Histologically confirmed diagnosis, according to the 2022 WHO classification, of one of the following lymphomas: Aggressive B cell lymphoma, including: * Diffuse large B cell lymphoma, not otherwise specified (DLBCL NOS) * High grade B cell lymphoma (HGBCL), including: 1. With MYC and BCL2 and/or BCL6 rearrangements (double hit/triple hit) 2. Not otherwise specified (i.e., without double/triple rearrangements) * Primary mediastinal B cell lymphoma (PMBL) * Transformed indolent B cell lymphoma, including: 1. Transformed follicular lymphoma (tFL) 2. Transformed marginal zone lymphoma (tMZL) 3. Transformed nodal or splenic B cell lymphomas, not otherwise specified (NOS) 4. Presence of measurable disease on pre treatment PET imaging, defined as at least one nodal lesion measurable in two dimensions, \> 1.5 cm in its largest dimension (and FDG avid), or at least one extranodal lesion measurable in two dimensions, \> 1.0 cm in its largest dimension (and FDG avid). 5. Requiring standard first line systemic therapy with curative intent. 6. Covered by a social security or health insurance system. 7. Able to speak and understand one of the official languages of the country, unless local regulations allow the use of independent interpreters. Exclusion Criteria: 1. Prior systemic anticancer treatment for the current lymphoma before study inclusion. All participants must be treatment naïve for the current lymphoma. Note: Short term corticosteroid use (e.g., for symptom control or during diagnostic workup) is permitted before inclusion and does not constitute an exclusion criterion. 2. Lymphomas arising in immunoprivileged sites (e.g., primary central nervous system lymphoma, primary testicular lymphoma, primary vitreoretinal lymphoma). 3. Absence of the mandatory blood sample for circulating tumor DNA (ctDNA) analysis during screening (pre treatment blood sample). 4. Absence of a pre treatment 18F FDG PET scan performed within ≤ 2 months prior to signing the informed consent form (mandatory PET imaging requirement). 5. Pregnant, breastfeeding, or intending to become pregnant women of childbearing potential. 6. Any significant medical condition, laboratory abnormality, or psychiatric disorder that may interfere with participation in this clinical study (as judged by the investigator). 7. Individuals deprived of liberty by judicial or administrative decision. 8. Individuals hospitalized without their consent. 9. Adults under legal protection.